Tango Therapeutics, Inc. 8-K

What Happened Tango Therapeutics (TNGX) filed an 8-K on January 8, 2026. The company reported $343 million in cash, cash equivalents and marketable securities as of December 31, 2025 (unaudited). Founder/CEO Barbara Weber, M.D. notified the board on January 7 and resigned as President and CEO effective January 8, 2026; she will serve as Executive Chair and chairperson of the board and provide advisory services through December 31, 2026. Board member Malte Peters, M.D. was appointed President and Chief Executive Officer effective January 8, 2026.

Key Details

• Cash position: $343 million as of December 31, 2025 (unaudited).
• Barbara Weber: will serve as Executive Chair under an amended agreement with a $362,000 annual base salary and a target cash bonus equal to 60% of her prior base salary, pro-rated for partial years; her resignation was not due to any disagreement with the company.
• Malte Peters: appointed CEO effective Jan 8, 2026; initial annual base salary $720,000 and 60% target cash bonus (pro-rated); granted an option for 1,650,000 shares (25% vest at 1 year, then monthly over 36 months) and 350,000 RSUs vesting in three equal annual installments.
• Corporate communications: the company issued a press release and updated investor presentation on Jan 8, 2026 (furnished as exhibits).

Why It Matters This 8-K combines a leadership transition with a snapshot of the company’s financial runway. The $343M cash and marketable securities figure is the key near-term financial metric investors use to assess capital resources. The CEO change introduces new executive leadership and significant equity awards to Malte Peters, while Barbara Weber remains involved as Executive Chair to support an orderly transition through year-end 2026. Investors should note the compensation and equity grant terms and the unaudited cash balance when evaluating near-term dilution and the company’s financial capacity to advance its programs.